News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
267,041 Results
Type
Article (14511)
Company Profile (283)
Press Release (252247)
Section
Business (80015)
Career Advice (152)
Deals (13345)
Drug Delivery (42)
Drug Development (51134)
Employer Resources (31)
FDA (5834)
Job Trends (5217)
News (145772)
Policy (10264)
Tag
Academia (909)
Alliances (21777)
Alzheimer's disease (845)
Antibody-drug conjugate (ADC) (116)
Approvals (5821)
Artificial intelligence (97)
Bankruptcy (103)
Best Places to Work (4654)
Biotechnology (232)
Breast cancer (153)
Cancer (1205)
Cardiovascular disease (89)
Career advice (132)
CAR-T (97)
Cell therapy (279)
Clinical research (41165)
Collaboration (447)
Compensation (185)
COVID-19 (1053)
C-suite (119)
Data (1179)
Diabetes (112)
Diagnostics (1288)
Earnings (29442)
Events (48129)
Executive appointments (356)
FDA (6353)
Funding (418)
Gene editing (76)
Gene therapy (202)
GLP-1 (347)
Government (1104)
Healthcare (6741)
Infectious disease (1105)
Inflammatory bowel disease (105)
IPO (7307)
Job creations (868)
Job search strategy (127)
Layoffs (201)
Legal (1403)
Lung cancer (194)
Lymphoma (80)
Manufacturing (114)
Medical device (2591)
Medtech (2592)
Mergers & acquisitions (6272)
Metabolic disorders (326)
Neuroscience (1159)
NextGen: Class of 2025 (2036)
Non-profit (861)
Northern California (1362)
Obesity (167)
Opinion (100)
Parkinson's disease (90)
Patents (91)
People (25465)
Phase I (14504)
Phase II (19106)
Phase III (12178)
Pipeline (517)
Postmarket research (861)
Preclinical (6044)
Radiopharmaceuticals (213)
Rare diseases (250)
Real estate (1440)
Regulatory (8668)
Research institute (940)
Series A (83)
Southern California (1191)
Startups (1971)
United States (10690)
Vaccines (204)
Weight loss (99)
Date
Today (29)
Last 7 days (343)
Last 30 days (1570)
Last 365 days (20784)
2025 (2691)
2024 (20941)
2023 (22703)
2022 (27106)
2021 (28008)
2020 (23553)
2019 (16439)
2018 (11903)
2017 (13868)
2016 (11937)
2015 (14469)
2014 (10475)
2013 (7562)
2012 (7609)
2011 (7669)
2010 (7470)
Location
Africa (155)
Asia (17443)
Australia (2906)
California (3077)
Canada (969)
China (284)
Colorado (115)
Connecticut (131)
Delaware (77)
Europe (37180)
Florida (354)
Georgia (91)
Illinois (192)
Japan (75)
Maryland (401)
Massachusetts (2411)
Minnesota (119)
New Jersey (800)
New York (851)
North Carolina (477)
Northern California (1362)
Ohio (98)
Pennsylvania (582)
South America (214)
Southern California (1191)
Texas (342)
Washington State (310)
267,041 Results for "adc therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Antibody-drug conjugate
Next-Gen ADCs Driving ‘Renaissance’ in Already Hot Oncology Drug Class
ADC Therapeutics, Sutro Biopharma and Zai Lab are among those developing antibody-drug conjugates to address payload and toxicity challenges of current ADCs—and rapidly grow the multibillion-dollar market.
November 25, 2024
·
7 min read
·
Greg Slabodkin
Press Releases
ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
January 30, 2025
·
1 min read
Press Releases
Myris Therapeutics is Developing Ultra-High DAR ADCs to Enable Novel Precision Medicine Treatments for Cancer
February 20, 2025
·
4 min read
Antibody-drug conjugate
Gilead Plots ADC Comeback With Potential $415M License Agreement
The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder cancer and its late-stage fail in NSCLC.
December 3, 2024
·
2 min read
·
Tristan Manalac
ADCs
GSK Turns Back to China in Another Potential $1B+ ADC Deal
One year after a potential $1.7 billion deal with Hansoh Pharma, GSK goes back to China to forge another alliance with DualityBio for another deal that could be worth up to $1 billion as it continues to build up its ADC portfolio.
December 4, 2024
·
1 min read
·
Kate Goodwin
Press Releases
DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development
February 13, 2025
·
1 min read
Lymphoma
Merck Touts 100% Complete Response Rate for Anti-ROR1 ADC as First-Line Lymphoma Treatment
Analysts called the data “very competitive” but raised questions about safety. Merck gained ownership of the ADC when it acquired VelosBio in November 2020 for $2.75 billion.
December 9, 2024
·
2 min read
·
Tristan Manalac
ADCs
Don’t Call It a Crossover, but Alentis Raises $181M Series D for ADC Work
CEO Roberto Iacone admitted in an interview that the market remains tough, even for a biotech in the red-hot ADC world. But Alentis is targeting an IPO as early as 2025.
November 12, 2024
·
2 min read
·
Annalee Armstrong
Press Releases
InxMed Presents Data regarding Potential Novel Way to Improve Therapeutic Window of ADC by Ifebemtinib and FIC ADC at 15th Annual World ADC
November 7, 2024
·
3 min read
Press Releases
ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial
December 9, 2024
·
2 min read
1 of 26,705
Next
